Table 1 General characteristics of surveyed medical doctors, bisphosphonate (BP) therapy and experience of bisphosphonate-related osteonecrosis of the jaw (BRONJ) patients (n = 192)
From: Perceptions of medical doctors on bisphosphonate-related osteonecrosis of the jaw
Group | N | Percent | |
|---|---|---|---|
Position | Specialists | 114 | 59.4 |
Residents | 78 | 40.6 | |
Specialty | Family medicine | 50 | 26.1 |
Orthopedics | 55 | 28.6 | |
Internal Medicine | 87 | 45.3 | |
Period of Career | <5 years | 69 | 35.9 |
5 ~ 10 years | 33 | 17.2 | |
10 ~ 20 years | 36 | 18.8 | |
>20 years | 54 | 28.1 | |
Indications for BP use | Osteoporosis | 160 | 83.3 |
Cancer | 31 | 16.2 | |
Others | 1 | 0.5 | |
Administration route of BP | Intravenous | 63 | 32.8 |
Oral | 127 | 66.2 | |
Other | 2 | 1.0 | |
Other adjuvant medications used with BP | Corticosteroids | 20 | 10.4 |
Chemotherapy | 22 | 11.5 | |
None | 150 | 78.1 | |
Number of patients on BP prescription per month | 1–10 | 111 | 57.8 |
11–20 | 26 | 13.5 | |
Over 21 | 55 | 28.7 | |
Experience of patients with BRONJ | Yes | 53 | 27.6 |
No | 115 | 59.9 | |
Do not know | 24 | 12.5 | |
Number of patients with BRONJ (n = 53) | 1–3 | 35 | 66.0 |
3–6 | 16 | 30.2 | |
Over 6 | 2 | 3.8 |